Go Pro
NASDAQ:SHPH

Shuttle Pharmaceuticals Q1 2025 Earnings Report

Shuttle Pharmaceuticals logo
$4.36 -0.02 (-0.46%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$4.30 -0.06 (-1.47%)
As of 08/7/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Shuttle Pharmaceuticals EPS Results

Actual EPS
-$75.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Shuttle Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shuttle Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Shuttle Pharmaceuticals Earnings Headlines

SHPH Share News Today
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Shuttle Pharmaceuticals Holdings Inc SHPH
Shuttle Pharmaceuticals Holdings, Inc.
See More Shuttle Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (NASDAQ:SHPH), a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

View Shuttle Pharmaceuticals Profile